Published by MyelinWatch:
CCMR Two · The completed CCMR2 study combined metformin and clemastine to explore whether they could support myelin repair.
CCMR2 combined metformin and clemastine, two existing medicines, to test a possible myelin-repair strategy. Experimental work suggests metformin may make precursor cells more responsive to repair signals, while clemastine may encourage their maturation into myelin-making cells; the trial tests the combination, not either drug alone.
Approach source: CCMR2 investigators — published trial protocol ↗
The completed CCMR2 study combined metformin and clemastine to explore whether they could support myelin repair.
Phase 2 study in people
Promising change in the brain's electrical response to vision
The study reported a change in the electrical response to vision, a biological signal. It did not find short-term improvement in disability; a full peer-reviewed paper and confirmation are still needed.
The finding is an early signal, not proof of patient benefit or an available treatment. The study is complete.
After 24 weeks, metformin plus clemastine shortened the delay in the brain's electrical response to vision, a change consistent with myelin repair. Vision and disability did not improve during the study's short follow-up.
Source: Cambridge Clinical MS Research Group — official academic research-group update ↗
